Literature DB >> 29926854

Discovery and synthesis of the first selective BAG domain modulator of BAG3 as an attractive candidate for the development of a new class of chemotherapeutics.

Stefania Terracciano1, Gianluigi Lauro, Alessandra Russo, Maria Carmela Vaccaro, Antonio Vassallo, Margot De Marco, Bianca Ranieri, Alessandra Rosati, Maria Caterina Turco, Raffaele Riccio, Giuseppe Bifulco, Ines Bruno.   

Abstract

BAG3 protein has emerged as a key regulator of important cellular processes and its expression is increased in some tumor types; however, despite its potential value for future chemotherapeutics, no selective BAG3 modulators have been yet reported. Here we report the 2,4-thiazolidinedione derivative 28 as the first BAG3 protein modulator.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29926854     DOI: 10.1039/c8cc03399d

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  5 in total

1.  Development of an anti-BAG3 humanized antibody for treatment of pancreatic cancer.

Authors:  Anna Basile; Margot De Marco; Michelina Festa; Antonia Falco; Vittoria Iorio; Luana Guerriero; Daniela Eletto; Domenica Rea; Claudio Arra; Alessia Lamolinara; Patrizia Ballerini; Verena Damiani; Alessandra Rosati; Gianluca Sala; Maria Caterina Turco; Liberato Marzullo; Vincenzo De Laurenzi
Journal:  Mol Oncol       Date:  2019-05-17       Impact factor: 6.603

Review 2.  At the Crossroads of Apoptosis and Autophagy: Multiple Roles of the Co-Chaperone BAG3 in Stress and Therapy Resistance of Cancer.

Authors:  Donat Kögel; Benedikt Linder; Andreas Brunschweiger; Silvia Chines; Christian Behl
Journal:  Cells       Date:  2020-02-28       Impact factor: 6.600

Review 3.  With or without You: Co-Chaperones Mediate Health and Disease by Modifying Chaperone Function and Protein Triage.

Authors:  Selin Altinok; Rebekah Sanchez-Hodge; Mariah Stewart; Kaitlan Smith; Jonathan C Schisler
Journal:  Cells       Date:  2021-11-11       Impact factor: 7.666

4.  Structural Refinement of 2,4-Thiazolidinedione Derivatives as New Anticancer Agents Able to Modulate the BAG3 Protein.

Authors:  Dafne Ruggiero; Stefania Terracciano; Gianluigi Lauro; Michela Pecoraro; Silvia Franceschelli; Giuseppe Bifulco; Ines Bruno
Journal:  Molecules       Date:  2022-01-20       Impact factor: 4.411

Review 5.  An emerging role for BAG3 in gynaecological malignancies.

Authors:  Margot De Marco; Antonia Falco; Roberta Iaccarino; Antonio Raffone; Antonio Mollo; Maurizio Guida; Alessandra Rosati; Massimiliano Chetta; Giovanni Genovese; Francesco De Caro; Mario Capunzo; Maria Caterina Turco; Vladimir N Uversky; Liberato Marzullo
Journal:  Br J Cancer       Date:  2021-06-07       Impact factor: 9.075

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.